The loss of BRCA1 function thus appears to be a double-edged sword: it may increase sensitivity to chemotherapy commonly used in breast and ovarian cancer and translate into favourable prognosis, but on the other side, it may trigger secondary leukaemogenesis. This evidence concerns the gene BRCA1 and ovarian carcinoma.